
Brainsway (BWAY) Stock Forecast & Price Target
Brainsway (BWAY) Analyst Ratings
Bulls say
BrainsWay Ltd has demonstrated a significant improvement in its operational efficiency, reflected by an over 50% increase in equipment utilization rates since the establishment of recent investments. The company is poised for enhanced revenue growth due to additional strategic investments that have been secured, enabling it to expand its market reach and operational capacity. Furthermore, the successful initial equity financing transaction serves as a favorable model for future financial undertakings, underpinning a robust framework for ongoing growth and development in the noninvasive neurostimulation sector.
Bears say
The negative outlook on BrainsWay's stock is driven by several fundamental risks, including the slower-than-projected adoption of its Deep TMS systems, which could hinder revenue growth. Additionally, the company's reliance on expanding reimbursement and market access poses a significant threat to its financial stability if it fails to secure necessary funding and support from healthcare payers. Finally, the ongoing risk of long-term dilution may impact shareholder value, particularly if BrainsWay cannot successfully advance its clinical trials for additional indications.
This aggregate rating is based on analysts' research of Brainsway and is not a guaranteed prediction by Public.com or investment advice.
Brainsway (BWAY) Analyst Forecast & Price Prediction
Start investing in Brainsway (BWAY)
Order type
Buy in
Order amount
Est. shares
0 shares